Pyelonephritis - Pipeline Review, H1 2014
出 版 商：Global Markets Direct
出版日期：2014/05/15
頁 數：52頁
文件格式：PDF
價 格：
USD 2,000 (Single-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
Pyelonephritis - Pipeline Review, H1 2014
Summary
Global Markets Direct’s, ‘Pyelonephritis - Pipeline Review, H1 2014’, provides an overview of the Pyelonephritis’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Pyelonephritis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pyelonephritis and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Pyelonephritis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Pyelonephritis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Pyelonephritis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Pyelonephritis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Pyelonephritis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Pyelonephritis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Summary
Global Markets Direct’s, ‘Pyelonephritis - Pipeline Review, H1 2014’, provides an overview of the Pyelonephritis’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Pyelonephritis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pyelonephritis and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Pyelonephritis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Pyelonephritis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Pyelonephritis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Pyelonephritis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Pyelonephritis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Pyelonephritis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Pyelonephritis Overview 6
Therapeutics Development 7
Pipeline Products for Pyelonephritis - Overview 7
Pipeline Products for Pyelonephritis - Comparative Analysis 8
Pyelonephritis - Therapeutics under Development by Companies 9
Pyelonephritis - Pipeline Products Glance 10
Late Stage Products 10
Clinical Stage Products 11
Early Stage Products 12
Pyelonephritis - Products under Development by Companies 13
Pyelonephritis - Companies Involved in Therapeutics Development 14
AstraZeneca PLC 14
Merck & Co., Inc. 15
Cubist Pharmaceuticals, Inc. 16
Achaogen Inc. 17
MerLion Pharmaceuticals Pte Ltd 18
Pyelonephritis - Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Combination Products 20
Assessment by Target 21
Assessment by Mechanism of Action 23
Assessment by Route of Administration 25
Assessment by Molecule Type 27
Drug Profiles 28
(ceftolozane + tazobactam) - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
(ceftazidime + avibactam) - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
plazomicin - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
finafloxacin - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
MK-7655 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
SkQ-1 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Pyelonephritis - Recent Pipeline Updates 39
Pyelonephritis - Dormant Projects 46
Pyelonephritis - Discontinued Products 47
Pyelonephritis - Product Development Milestones 48
Featured News & Press Releases 48
May 07, 2013: Cubist’s Late-stage Antibiotic Candidate CXA-201 Receives FDA Fast Track Designation 48
May 24, 2012: European Medicines Agency Completes Review Of Sanofi's Tavanic 48
May 15, 2012: Achaogen Provides Update On Phase II Study Of Plazomicin 49
Sep 30, 2008: Taisho Toyama Launches Zosyn In Japan 50
Appendix 51
Methodology 51
Coverage 51
Secondary Research 51
Primary Research 51
Expert Panel Validation 51
Contact Us 52
Disclaimer 52
List of Tables
Number of Products under Development for Pyelonephritis, H1 2014 7
Number of Products under Development for Pyelonephritis - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 9
Comparative Analysis by Late Stage Development, H1 2014 10
Comparative Analysis by Clinical Stage Development, H1 2014 11
Comparative Analysis by Early Stage Development, H1 2014 12
Products under Development by Companies, H1 2014 13
Pyelonephritis - Pipeline by AstraZeneca PLC, H1 2014 14
Pyelonephritis - Pipeline by Merck & Co., Inc., H1 2014 15
Pyelonephritis - Pipeline by Cubist Pharmaceuticals, Inc., H1 2014 16
Pyelonephritis - Pipeline by Achaogen Inc., H1 2014 17
Pyelonephritis - Pipeline by MerLion Pharmaceuticals Pte Ltd, H1 2014 18
Assessment by Monotherapy Products, H1 2014 19
Assessment by Combination Products, H1 2014 20
Number of Products by Stage and Target, H1 2014 22
Number of Products by Stage and Mechanism of Action, H1 2014 24
Number of Products by Stage and Route of Administration, H1 2014 26
Number of Products by Stage and Molecule Type, H1 2014 27
Pyelonephritis Therapeutics - Recent Pipeline Updates, H1 2014 39
Pyelonephritis - Dormant Projects, H1 2014 46
Pyelonephritis - Discontinued Products, H1 2014 47
List of Figures
Number of Products under Development for Pyelonephritis, H1 2014 7
Number of Products under Development for Pyelonephritis - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 9
Assessment by Monotherapy Products, H1 2014 19
Number of Products by Top 10 Target, H1 2014 21
Number of Products by Stage and Top 10 Target, H1 2014 22
Number of Products by Top 10 Mechanism of Action, H1 2014 23
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 24
Number of Products by Top 10 Route of Administration, H1 2014 25
Number of Products by Stage and Top 10 Route of Administration, H1 2014 26
Number of Products by Stage and Top 10 Molecule Type, H1 2014 27
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Pyelonephritis Overview 6
Therapeutics Development 7
Pipeline Products for Pyelonephritis - Overview 7
Pipeline Products for Pyelonephritis - Comparative Analysis 8
Pyelonephritis - Therapeutics under Development by Companies 9
Pyelonephritis - Pipeline Products Glance 10
Late Stage Products 10
Clinical Stage Products 11
Early Stage Products 12
Pyelonephritis - Products under Development by Companies 13
Pyelonephritis - Companies Involved in Therapeutics Development 14
AstraZeneca PLC 14
Merck & Co., Inc. 15
Cubist Pharmaceuticals, Inc. 16
Achaogen Inc. 17
MerLion Pharmaceuticals Pte Ltd 18
Pyelonephritis - Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Combination Products 20
Assessment by Target 21
Assessment by Mechanism of Action 23
Assessment by Route of Administration 25
Assessment by Molecule Type 27
Drug Profiles 28
(ceftolozane + tazobactam) - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
(ceftazidime + avibactam) - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
plazomicin - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
finafloxacin - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
MK-7655 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
SkQ-1 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Pyelonephritis - Recent Pipeline Updates 39
Pyelonephritis - Dormant Projects 46
Pyelonephritis - Discontinued Products 47
Pyelonephritis - Product Development Milestones 48
Featured News & Press Releases 48
May 07, 2013: Cubist’s Late-stage Antibiotic Candidate CXA-201 Receives FDA Fast Track Designation 48
May 24, 2012: European Medicines Agency Completes Review Of Sanofi's Tavanic 48
May 15, 2012: Achaogen Provides Update On Phase II Study Of Plazomicin 49
Sep 30, 2008: Taisho Toyama Launches Zosyn In Japan 50
Appendix 51
Methodology 51
Coverage 51
Secondary Research 51
Primary Research 51
Expert Panel Validation 51
Contact Us 52
Disclaimer 52
List of Tables
Number of Products under Development for Pyelonephritis, H1 2014 7
Number of Products under Development for Pyelonephritis - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 9
Comparative Analysis by Late Stage Development, H1 2014 10
Comparative Analysis by Clinical Stage Development, H1 2014 11
Comparative Analysis by Early Stage Development, H1 2014 12
Products under Development by Companies, H1 2014 13
Pyelonephritis - Pipeline by AstraZeneca PLC, H1 2014 14
Pyelonephritis - Pipeline by Merck & Co., Inc., H1 2014 15
Pyelonephritis - Pipeline by Cubist Pharmaceuticals, Inc., H1 2014 16
Pyelonephritis - Pipeline by Achaogen Inc., H1 2014 17
Pyelonephritis - Pipeline by MerLion Pharmaceuticals Pte Ltd, H1 2014 18
Assessment by Monotherapy Products, H1 2014 19
Assessment by Combination Products, H1 2014 20
Number of Products by Stage and Target, H1 2014 22
Number of Products by Stage and Mechanism of Action, H1 2014 24
Number of Products by Stage and Route of Administration, H1 2014 26
Number of Products by Stage and Molecule Type, H1 2014 27
Pyelonephritis Therapeutics - Recent Pipeline Updates, H1 2014 39
Pyelonephritis - Dormant Projects, H1 2014 46
Pyelonephritis - Discontinued Products, H1 2014 47
List of Figures
Number of Products under Development for Pyelonephritis, H1 2014 7
Number of Products under Development for Pyelonephritis - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 9
Assessment by Monotherapy Products, H1 2014 19
Number of Products by Top 10 Target, H1 2014 21
Number of Products by Stage and Top 10 Target, H1 2014 22
Number of Products by Top 10 Mechanism of Action, H1 2014 23
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 24
Number of Products by Top 10 Route of Administration, H1 2014 25
Number of Products by Stage and Top 10 Route of Administration, H1 2014 26
Number of Products by Stage and Top 10 Molecule Type, H1 2014 27
